-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Akebia Therapeutics (NASDAQ:AKBA) Now Covered by StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Now Covered by StockNews.com
Research analysts at StockNews.com began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research note issued on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Separately, HC Wainwright dropped their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research note on Monday, May 16th. Seven equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $1.75.
Get Akebia Therapeutics alerts:Akebia Therapeutics Price Performance
Shares of AKBA opened at $0.44 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 1.30. The company has a market capitalization of $79.99 million, a price-to-earnings ratio of -0.46 and a beta of 1.50. Akebia Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.35. The firm has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.76.
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.54. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. The company had revenue of $126.76 million during the quarter, compared to analysts' expectations of $49.10 million. During the same period last year, the company posted ($0.51) earnings per share. On average, equities research analysts anticipate that Akebia Therapeutics will post -0.44 earnings per share for the current year.Institutional Trading of Akebia Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of AKBA. Point72 Hong Kong Ltd acquired a new position in shares of Akebia Therapeutics in the 4th quarter valued at $30,000. BNP Paribas Arbitrage SA increased its stake in Akebia Therapeutics by 123.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 50,066 shares during the period. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $40,000. Finally, MetLife Investment Management LLC increased its stake in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 54,389 shares during the period. 31.56% of the stock is owned by hedge funds and other institutional investors.
Akebia Therapeutics Company Profile
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Featured Articles
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Research analysts at StockNews.com began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research note issued on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
斯托克新闻网的研究分析师在周一发布的一份研究报告中开始报道木通治疗公司(纳斯达克：AKBA-GET评级)的股票。该经纪公司对这家生物制药公司的股票设定了“持有”评级。
Separately, HC Wainwright dropped their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research note on Monday, May 16th. Seven equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $1.75.
另外，在5月16日星期一的一份研究报告中，HC Wainwright将木通治疗公司的股票目标价从2.00美元下调至1.25美元。根据MarketBeat.com的数据，七位股票研究分析师对该股的评级为持有，该公司目前的平均评级为持有，平均目标价为1.75美元。
Akebia Therapeutics Price Performance
木通治疗药物的价格表现
Shares of AKBA opened at $0.44 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 1.30. The company has a market capitalization of $79.99 million, a price-to-earnings ratio of -0.46 and a beta of 1.50. Akebia Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.35. The firm has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.76.
周一，AKBA的股价开盘报0.44美元。该公司的负债权益比率为0.51，速动比率为1.15，流动比率为1.30。该公司市值为7,999万美元，市盈率为-0.46，贝塔系数为1.50。木通治疗公司的股价跌至0.30美元的52周低点和3.35美元的52周高点。该公司的50日简单移动均线切入位为0.41美元，200日简单移动均线切入位为0.76美元。
Institutional Trading of Akebia Therapeutics
木通治疗的制度性交易
Several hedge funds and other institutional investors have recently bought and sold shares of AKBA. Point72 Hong Kong Ltd acquired a new position in shares of Akebia Therapeutics in the 4th quarter valued at $30,000. BNP Paribas Arbitrage SA increased its stake in Akebia Therapeutics by 123.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 50,066 shares during the period. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $40,000. Finally, MetLife Investment Management LLC increased its stake in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 54,389 shares during the period. 31.56% of the stock is owned by hedge funds and other institutional investors.
几家对冲基金和其他机构投资者最近买卖了AKBA的股票。Point72 Hong Kong Ltd在第四季度收购了木通治疗公司的新股份，价值3万美元。法国巴黎银行套利公司在第二季度将其在木通治疗公司的股份增加了123.7%。法国巴黎银行套利公司现在持有90,540股这家生物制药公司的股票，价值3.2万美元，在此期间又购买了50,066股。GSA Capital Partners LLP在第一季度购买了木通治疗公司价值39,000美元的新股份。Mirabella Financial Services LLP在第一季度购买了Akebia治疗公司价值4万美元的新股份。最后，大都会人寿投资管理有限责任公司在第一季度将其在木通治疗公司的股份增加了176.6%。大都会人寿投资管理公司现在拥有85,186股这家生物制药公司的股票，价值61,000美元，在此期间又购买了54,389股。31.56%的股票由对冲基金和其他机构投资者持有。
Akebia Therapeutics Company Profile
木通治疗公司简介
(Get Rating)
(获取评级)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治疗公司是一家生物制药公司，专注于肾脏疾病患者治疗药物的开发和商业化。该公司的主要研究产品候选产品是vadustat，这是一种口服疗法，正处于第三阶段开发，用于治疗依赖透析和非透析依赖的成年患者的慢性肾脏疾病(CKD)引起的贫血。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免费获取StockNews.com关于木通治疗的研究报告(AKBA)
- 电子艺界能扭转电子游戏市场的低迷吗？
- 美元将军是美国小池塘里的大鱼。
- 以下是CPI报告将决定市场底部的原因
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对木通治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧